Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
144 studies found for:    Immunodeficiency NOT AIDS | Open Studies
Show Display Options
Rank Status Study
21 Recruiting Diagnostic Immunization With Rabies Vaccine in Patients With PID
Condition: Primary Immunodeficiency
Intervention: Biological: Verorab® (PVRV; Purified Vero Cell Vaccine)
22 Recruiting Immune Regulation in Patients With Common Variable Immunodeficiency and Related Syndromes
Condition: CVID
23 Recruiting A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push
Condition: Primary Immunodeficiency
Interventions: Device: Chrono Super PID then Generic Syringe-Gammanorm;   Device: Generic Syringe then Chrono Super PID-Gammanorm
24 Recruiting Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps
Condition: Primary Immunodeficiency (PID)
Intervention: Biological: Gammanorm
25 Recruiting Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency
Condition: Primary Immunodeficiency
Intervention: Biological: IGSC 20%
26 Recruiting Study of Octanorm Subcutaneous IG in Patients With Primary Immunodeficiency Diseases Who Have Completed the SCGAM-01 Trial
Condition: Primary Immunodeficiency Disease
Intervention: Drug: Octanorm 16.5%
27 Not yet recruiting Clinical Trial to Assess the Efficacy of Rituximab and Azathioprine in the Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) in Adult Patients With Common Variable Immunodeficiency (CVID)
Condition: Granulomatous and Lymphocytic Interstitial Lung Disease
Interventions: Drug: Rituximab (RTX) and Azathioprine (AZA);   Drug: Placebo Administration
28 Recruiting Assessment of Immunoglobulins (IgG) in a Long-term Non-interventional Study
Conditions: Primary Immunodeficiency (PID);   Secondary Immunodeficiency (SID);   Neurological Autoimmune Disease
Intervention: Other: Immunoglobulin G (IgG)
29 Recruiting Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases
Conditions: Severe Combined Immunodeficiency (SCID);   Immunodeficiency With Predominant T-cell Defect, Unspecified;   Severe Chronic Neutropenia;   Chronic Granulomatous Disease (CGD);   Hyper IgE Syndromes;   Hyper IgM Deficiencies;   Wiskott-Aldrich Syndrome;   Mendelian Susceptibility to Mycobacterial Disease;   Common Variable Immune Deficiency (CVID)
Intervention: Biological: CD3/CD19 negative allogeneic hematopoietic stem cells
30 Recruiting Gene Transfer for Severe Combined Immunodeficiency, X-linked (SCID-X1) Using a Self-inactivating (SIN) Gammaretroviral Vector
Condition: Severe Combined Immunodeficiency
Intervention: Biological: Gene transfer
31 Recruiting EZN-2279 in Patients With ADA-SCID
Conditions: ADA-SCID;   Adenosine Deaminase Deficiency;   Severe Combined Immunodeficiency
Interventions: Biological: EZN-2279;   Biological: Adagen
32 Available Expanded Access Protocol Thymus Transplantation
Conditions: Poor Thymic Function;   Immunodeficiency;   Athymia;   Immunoreconstitution;   Thymus Transplantation;   Low T Cell Numbers
Interventions: Biological: Thymus Transplantation;   Procedure: Blood Draw;   Drug: Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus
33 Not yet recruiting Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID
Condition: Immunodeficiency Primary
Intervention: Biological: BT595
34 Not yet recruiting Improving the Diagnosis of Common Variable Immune Deficiency
Condition: Common Variable Immune Deficiency (CVID)
35 Unknown  Bronchial Inflammation in Patients With Severe Immune Deficiency Under Immunoglobulin Treatment
Condition: Immune Deficiency
36 Unknown  Evaluation of Efficacy and Tolerability of Hizentra®
Condition: Primary Immunodeficiency Disorders
Intervention: Drug: Hizentra
37 Recruiting TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID
Conditions: Primary Immune Deficiency Disorder;   Hematopoietic Stem Cell Transplantation
Intervention: Other: Biological: TCR alfa beta T cell depletion
38 Recruiting Magnesium Supplementation in People With XMEN Syndrome
Conditions: X-linked Immunodeficiency With Magnesium Defect;   Epstein-Barr Virus (EBV) Infection and Neoplasia
Interventions: Drug: Magnesium L-threonate;   Drug: Placebo;   Drug: Magnesium Sulfate (MgSO)
39 Recruiting Reduced Intensity Conditioning in Patients Aged ≤35 With Non-Malignant Disorders Undergoing UCBT, BMT, or PBSCT
Conditions: Primary Immunodeficiency Syndromes;   Congenital Bone Marrow Failure Syndromes;   Inherited Metabolic Disorders (IMD);   Hereditary Anemias;   Patients With Sickle Disease Presenting Specific Symptoms
Interventions: Drug: Hydroxyurea;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa
40 Unknown  Evaluate Bacteriophage as a Useful Immunogen in Patients With Primary Immune Deficiency Diseases (PIDD)
Condition: Primary Immune Deficiency Diseases
Intervention: Biological: Bacteriophage OX174

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years